Gender Differences in Patients with Prolactinoma: Single-center Ukrainian Experience
- PMID: 38561622
- DOI: 10.2174/0115748871288948240325080936
Gender Differences in Patients with Prolactinoma: Single-center Ukrainian Experience
Abstract
Introduction: Prolactinomas are the most common type of pituitary gland tumors that secrete overly prolactin. They account for approximately 60% of all hormone-secreting hypophysis tumors.
Aim: This study aims to analyze gender differences in patients with prolactinomas who were operated on transsphenoidal surgery and conduct a single-center retrospective analysis of patient data.
Material and methods: This study evaluated the medical records of 109 patients (61 females and 48 males) from 2009 to 2019 at Feofaniya Clinical Hospital of the State Administration of Affairs in Kyiv, Ukraine. The primary criterion for including patients was a Serum Prolactin (PRL) level of over 100 ng/ml and the presence of a pituitary adenoma (PA) as observed on MRI. Additionally, the histological examination needed to confirm the presence of Prolactin-Secreting Pituitary Adenomas (PSPAs) without plurihormonal activity through both microscopy and immunohistochemical (IHC) staining.
Results: Significant differences in preoperative PRL levels were not observed. However, males had significantly larger tumor sizes and prevalence of macroadenomas. In male patients, the preoperative PLR levels showed a weak negative correlation with age (r=-0.304, p < 0.036) and a positive correlation with tumor size (r=0.555, p < 0.001) and cavernous sinus invasion (r=0.339, p < 0.018). In females, preoperative PRL was significantly associated only with tumor size and Knosp grade.
Conclusion: Prolactin-Secreting Pituitary Adenomas (PSPAs) are more common in women than men and are characterized by larger and more invasive tumors with high PRL levels at diagnosis. The PRL level and tumor size before surgery can predict early biochemical remission in both males and females with an accuracy of 58.3% and 68.8%, respectively.
Keywords: Prolactinomas; dopamine agonists; pituitary adenomas; prolactin; trans-sphenoidal surgery; tumor..
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Similar articles
-
Prognostic factors for surgical treatment of prolactin-secreting pituitary adenomas.Front Surg. 2024 Feb 5;11:1283179. doi: 10.3389/fsurg.2024.1283179. eCollection 2024. Front Surg. 2024. PMID: 38375408 Free PMC article.
-
Magnetic resonance imaging measurements of pituitary stalk compression and deviation in patients with nonprolactin-secreting intrasellar and parasellar tumors: lack of correlation with serum prolactin levels.Neurosurgery. 1994 May;34(5):834-9; discussion 839. doi: 10.1227/00006123-199405000-00007. Neurosurgery. 1994. PMID: 8052379 Clinical Trial.
-
Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.Clin Endocrinol (Oxf). 2000 Apr;52(4):437-45. doi: 10.1046/j.1365-2265.2000.00951.x. Clin Endocrinol (Oxf). 2000. PMID: 10762286 Clinical Trial.
-
Diagnosis and treatment of pituitary adenomas.Minerva Endocrinol. 2004 Dec;29(4):241-75. Minerva Endocrinol. 2004. PMID: 15765032 Review.
-
[Prolactin producing adenoma].Nihon Rinsho. 1993 Oct;51(10):2685-90. Nihon Rinsho. 1993. PMID: 8254940 Review. Japanese.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical